Скачать или смотреть Strides Pharma Q1FY26 Results: Operational PAT Skyrockets 80.6%

Link to our Twitter Profile - https://x.com/intent/user?screen_name...
Link to our Telegram Channel - https://t.me/niftybn
Link to our Instagram Handle -   / niftybn_  
Link to our Facebook Page - https://fb.com/niftybn

Strides Pharma Q1FY26 Results: Operational PAT Skyrockets 80.6% 🚀
📅 July 29, 2025

Strides Pharma delivered a robust Q1FY26, driven by stellar operational performance and solid revenue expansion. Total revenue for the quarter rose 6.2% year-over-year to ₹11,197 million. EBITDA surged by 14.8% YoY to ₹2,181 million, lifting EBITDA margins to 19.5% (up 150bps). Most notably, Operational Profit After Tax (PAT) soared 80.6% YoY, reaching ₹1,140 million, and resulting in an Operational EPS of ₹12.4.

Key Highlights 🌟:

📈 Revenue: ₹11,197 million (+6.2% YoY)

💹 EBITDA: ₹2,181 million (+14.8% YoY); Margin improved to 19.5%

🚀 Operational PAT: ₹1,140 million (+80.6% YoY); EPS: ₹12.4

🇺🇸 US market revenue: US$71 million (+7.0% YoY); first 'Beyond Generics' Nasal Spray filed

🌍 Other Regulated Markets: Up 9.2% YoY to US$42 million

⬇️ Access Markets: Down 72.9% due to lower donor funding

🏦 Net debt reduced to ₹14,958 million; Credit upgraded to 'CARE A Positive'

🔬 Strategic priority: Enhance R&D, targeting US$400 million in US revenues by FY27-28

Strides’ fortified balance sheet and commitment to R&D underpin an optimistic outlook for sustainable growth and expanding global presence.

#StridesPharma #Q1Results #FinancialResults #PAT #EBITDA #EPS #Pharma #USMarket #Generics #NasalSpray #RevenueGrowth #DebtReduction #CreditRating #India #Healthcare #Pharmaceuticals #BusinessUpdate #Investing #Earnings #R&D #CorporateUpdates #GrowthProspects